Patients will often notice improvements in addition to their area of concern
Acknowledgements The authors would like to thank the Italian Society of Diabetes (SID) for having reviewed the content of the manuscript and agreed with it Funding Open access funding provided by Universit degli Studi di Roma La Sapienza within the CRUI-CARE Agreement
Retatrutide remains investigational: it is not FDA-approved, and all human timeline claims should be read as clinical-trial evidence, not personal dosing guidance
These are dosed in milligrams directly, without the intermediate step of unit conversion
A well-rounded approach includes monitoring body composition, metabolic health, daily symptoms, and overall quality of life
Yes, you can substitute ingredients based on availability or dietary preferences